Recent Updates — HRGN
On September 11, 2026, Harvard Apparatus Regenerative Technology, Inc. closed a private placement of 2,703,727 shares of common stock for an aggregate purchase price of $2,838,911 at $1.05 per share. CEO Jerry (Junli) He purchased 683,725 shares by converting and cancelling $717,911 in outstanding principal and accrued interest from bridge promissory notes issued between April and July 2026. The transaction was conducted under Section 4(a)(2) exemptions for accredited investors. Harvard Apparatus Regenerative Technology operates in the medical device industry, specifically developing regenerative medicine technologies.
Harvard Apparatus Regenerative Technology entered into two related-party bridge notes with Chairman and CEO Junli He for a total of $400,000 ($200,000 each). The May Bridge Note was executed on May 8, 2026, and the July Bridge Note on July 16, 2026. Both notes accrue interest at an annual fixed rate of 8% and mature on the earlier of a qualifying capital raise with gross proceeds of at least $5 million or their respective one-year anniversaries. The outstanding balances may be converted into equity at the purchaser's price if the company raises at least $200,000 in new equity before maturity. These transactions were approved by disinterested board members. Harvard Apparatus Regenerative Technology operates in the biotechnology and medical device industry, focusing on regenerative medicine technologies.
Harvard Apparatus Regenerative Technology entered into a $300,000 bridge note with Chairman and CEO Junli He on April 13, 2026. The loan accrues interest at an annual fixed rate of 8% and matures on the earlier of April 13, 2027, or the closing of a subsequent capital raise generating at least $5,000,000 in gross proceeds. The note includes optional conversion rights for the lender, standard covenants, and customary events of default. This filing corrects the original report's classification from Item 1.02 to Item 1.01. The company operates in the medical device industry, specializing in regenerative medicine technologies.